INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer | 最新消息 - 中國醫藥大學附設醫院

:::

院外單位健康通報

實名登記系統

"> 回首頁LOGO按鈕

繁簡 EN

最新消息

News & Message

:::

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer

最新消息

2026/2/3

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer

回上頁

相關文章

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

側邊開關圖示

中國醫點通

百度搜狗 360搜索五福临门危情迷踪女老板执魔道士不好惹

<code id='428d4'></code><style id='4645e'></style>

<acronym id='01aa7'></acronym>

<center id='61be3'><center id='a71d2'><tfoot id='eeebf'></tfoot></center><abbr id='e79e1'><dir id='d4cfa'><tfoot id='6888e'></tfoot><noframes id='6f87b'>

<optgroup id='1bed5'><strike id='d9327'><sup id='6a040'></sup></strike><code id='0673b'></code></optgroup>

<b id='55b29'><label id='a1005'><select id='e9491'><dt id='bc2e5'><span id='f9086'></span></dt></select></label></b><u id='5326c'></u>

~~<i id='1838f'><strike id='6327a'><tt id='469e0'><pre id='8cebf'></pre></tt></strike></i>~~